Lesogaberan

Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABAB receptor agonist,[3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]

Lesogaberan
Names
Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid
Other names
AZD-3355
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.133.162
UNII
  • InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 ☒N
    Key: LJNUIEQATDYXJH-GSVOUGTGSA-N ☒N
  • InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1
    Key: LJNUIEQATDYXJH-GSVOUGTGBQ
  • O=[PH](O)C[C@H](F)CN
Properties
C3H9FNO2P
Molar mass 141.082 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

References
  1. AstraZeneca. "AZD3355". Retrieved 30 December 2011.
  2. Bredenoord, Albert J. (2009). "Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID 19697277.
  3. Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. doi:10.1021/jm701425k. PMID 18578471.
  4. Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661. S2CID 258021903.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.